Kornimate/medical-research-clean huggingface dataset:
study of the impact of a targeted decolonization of s. aureus persistent carriers

Conditions: Hemodialysis Patients

Summary: s. aureus nasal carriage is a well-known risk factor for s. aureus infections in hemodialysis (hd) patients. strains of carriage and infections are the same in \>80% of cases we recently shown that persistent carriers of s. aureus, not intermittent ones are at increased risk of staphylococcal infections in hd. thanks to a new algorithm developped based on one nasal sample the determination of carriage status (persistent, intermittent or non-carriers) among patients is easy. mupirocin use in hd have been shown to reduce significantly s. aureus infections however, multiples schedules of decolonization have been proposed to all s. aureus carriers. to date, there is no national guideline for decolonization of s. aureus in hd. we showed that only 50% of hd centers in france propose screening and decolonization of s. aureus carriers. the aim of the study is therefore to evaluate the impact of a targeted decolonization of s. aureus persistent carriers using mupirocin nasal ointment and chlorhexidine baths during 5 days on the occurrence of s. aureus infections in hd patients compared to the absence of decolonization using a randomized open study methodology.

hemodialysis patients will be randomized in 2 arms: one arm where persistent carriers will be decolonized. decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. screening of persistent carriers in this arm will be done every 3 months and a new decolonization will be proposed to patients found (again) persistent carriers. determination of carriage status will be done using one nasal swab by following the algorithm previously described. bacterial load will be determined by a quantitative s. aureus pcr (polymerase chain reaction) : persistent carriers are the patient with a bacterial load \> 103 cfu/ml (colony forming unit) . the other arm is hd patients in which decolonization is not performed including impersistent carriers. all infections that occurred in enrolled patients will be counted in both groups

Eligibility criteria:
inclusion criteria: * adults (age ≥ 18 years-old) * patient under chronic hemodialysis * patent that accepted to participate in the study with a written consent form signed exclusion criteria: * patients under peritoneal dialysis * patients with an active infection at the time of inclusion * patients previously treated by mupirocin and chlorhexidine for decolonization purpose * patients that received antimicrobials active on s. aureus during the month before the inclusion * patients with allergy to mupirocin or chlorhexidine * patients treated by hemodialysis transiently (non-terminal kidney failure) * pregnancy

Keywords: hemodialysis s. aureus decolonization persistent carriage
further development and initial testing of restore in frontline workers

Conditions: Mental Health; PTSD; Anxiety; Depressive Symptoms

Summary: there is considerable need for psychological intervention targeting stressor-related mental health symptoms related to covid-19. the investigators have developed an online self-directed transdiagnostic intervention to address this need called restore: recovering from extreme stressors through online resources and e-health. the specific aims of this project are to refine and investigate the feasibility, initial safety, and efficacy of restore for addressing mental health symptoms in first responders, health care workers (hcw), and canadian armed forces members exposed to covid-19-related traumatic or extreme stressors.

this uncontrolled pilot interventional study will examine the feasibility and preliminary efficacy of restore. restore is a guided self-directed online intervention to improve anxiety, depression, and posttraumatic stress disorder (ptsd) in individuals exposed to covid-19 related traumatic or extreme stressors. restore is based on evidence-based psychotherapies and has been designed to overcome many of the barriers associated with accessing evidence-based psychotherapies. the intervention will be iteratively refined over the course of the study. the guidance methods will also be refined and manualized over the course of the study the primary hypotheses are that restore will be safe, feasible, and desirable to participants, and will lead to improvements in mental health symptom severity from baseline to post-intervention. secondary hypotheses are that restore will lead to significant improvements in perceived health, quality of life, and functioning from baseline to post-intervention. participants will be assessed at baseline, pre-intervention, during the intervention (after module 4), immediately after the intervention, and 1 month after completion of the intervention.

Eligibility criteria:
inclusion criteria: * canadian healthcare worker, first responder, or military member * experienced a traumatic or extremely stressful situation in the course of work related to covid-19 * ≥ 18 years of age * scores at above clinical threshold, as defined by the investigators, on at least one of: patient health questionnaire-9 (\[phq-9\] score ≥ 10), generalized anxiety disorder scale-7 (\[gad-7\] score ≥ 10), and/or posttraumatic stress disorder scale-5 (\[pcl-5\] score ≥ 33) * access to a computer or a tablet with high speed internet access, be able to clearly see the screen of a computer or tablet, and be fluent in english * ability to provide consent exclusion criteria: * elevated risk of suicide * currently enrolled in another intervention or treatment (e.g., cognitive behavioural therapy) for stress responses related to the covid-19 pandemic

Keywords: ehealth intervention covid-19 mental health
clinical and paraclinical characteristics of the systemic scleroderma cohort according to the criteria acr 2013 and the history of professional exposure or of agricultural environment

Conditions: Systemic Scleroderma

Summary: the aim of the study is to compare the exposure to environmental and professional toxics by patients with systemic scleroderma and by patients not achieved by this pathology.

this study is based on a questionnaire. the data will be collected according a retrospective and prospective design : * at diagnostic of the disease * at the inclusion in the systemic scleroderma cohort * during the annual visit (in 2017-2018-2019-2020)

Eligibility criteria:
inclusion criteria: * patients with systemic scleroderma exclusion criteria: -

Keywords: systemic scleroderma environmental and professional toxics
a study to evaluate chronic hepatitis c virus (hcv) infection in cirrhotic adults with genotype 1b (gt1b) infection

Conditions: Chronic Hepatitis C Virus (HCV) Infection

Summary: this was a multicenter study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with ribavirin (rbv) for 12 weeks in treatment naïve and pegylated-interferon alfa-2a or alfa-2b (pegifn)/rbv treatment-experienced, cirrhotic hcv genotype 1b-infected adults.

the primary objective of this study was to assess the safety and efficacy (the percentage of participants achieving a 12-week sustained virologic response (svr12), \[hcv ribonucleic acid (rna) \< lower limit of quantification (lloq) 12 weeks following treatment\]) of co-formulated ombitasvir, paritaprevir, and ritonavir (ombitasvir/paritaprevir/r) and dasabuvir co-administered with rbv for 12 weeks in hcv genotype 1b-infected adult participants with compensated cirrhosis. the secondary objectives of this study were to assess the number and percentage of participants with virologic failure during treatment and the percentage of participants with relapse post-treatment.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c, genotype 1b-infection (hcv rna level greater than 1,000 iu/ml at screening) * evidence of liver cirrhosis as confirmed by liver biopsy or fibroscan with child-pugh score less than or equal to 6 at screening * participant had never received antiviral treatment (including pegifn/rbv) for hepatitis c infection (treatment-naïve participant) or had documentation of meeting one of the defined categories of a treatment-experienced participants * absence of hepatocellular carcinoma (hcc) as indicated by a negative ultrasound, computed tomography (ct) scan, or magnetic resonance imaging (mri) performed within 3 months prior to screening or a negative ultrasound at screening. * females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control * males must have been surgically sterile, or agreed to practice 2 effective methods of birth control throughout the course of the study. exclusion criteria: * positive screen for hepatitis b surface antigen or anti-human immunodeficiency virus antibody * evidence of current or past child-pugh b or c classification * confirmed presence of hepatocellular carcinoma * abnormal laboratory tests * participant who self-reported on average drinking more than 2 drinks per day for current drinkers * previous treatment with a direct acting antiviral agent (daa) containing regimen * history of solid organ transplant.

Keywords: chronic hepatitis c hepatitis c hepatitis c virus hepatitis c genotype 1b interferon-free
evolve china pmcf study

Conditions: Intracranial Aneurysm

Summary: a prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. the expected duration of the study is 8 years (including up to 5-years' follow-up). each subject will be followed up per standard of care (soc) at each study site.


Eligibility criteria:
inclusion criteria: * subject age is ≥ 18 and ≤80 years * subject is eligible for surpass evolve fds ifu, and/or physician intends to treat the subject with surpass evolve fds per his/her judgement * subject, or subject's legally authorised representative (lar) has provided signed informed consent using the ethics committee (ec)-approved consent form * subject is willing to comply with scheduled visits and examinations per institutional soc exclusion criteria: * subject has any non-target intracranial aneurysm treated within 30 days prior to study enrollment * subject has a planned treatment of a non-target aneurysm in the same vascular territory during participation in the study within 12 months post procedure * subject has undergone previous treatment where it would interfere with the delivery and/ or placement and/or proper apposition of surpass evolve fds * subject has acute target aneurysm rupture and/or subarachnoid hemorrhage occurred within 30 days prior to enrollment * subject has any condition demonstrated as warning or precautions in ifu * antiplatelet and/or anticoagulation therapy (e.g. aspirin and clopidogrel) is contraindicated for the subject * subject has not received dual anti-platelet agents prior to the procedure * subject with an active bacterial infection * subject in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment, due to conditions such as: * severe intracranial vessel tortuosity or stenosis; and/or * intracranial vasospasm not responsive to medical therapy * female subjects who are pregnant/ nursing, or who are unwilling or unable to take adequate method of contraception prior to the 12-month study follow-up.\* \*if the subject becomes pregnant during her participation, the physician will have to evaluate the risk associated to her continuing participation to the rest of the study. * enrollment in another trial involving an investigational product and/or drug interfere with study procedure/ results * the investigator determined that the health of the patient may be compromised by the patient's enrollment
immunoglobulin g antibody immune response profile following infection with sars-cov-2 in covid-19 egyptian patients

Conditions: Covid19

Summary: the objective of this study is to detect the evidence on the immune response following acute sars-cov-2 infections. the study will report the profile of igg specific antibodies levels to sars-cov-2 infection found in recovered coronavirus disease (covid-19) patients after infection for both symptomatic and asymptomatic patients.

a total of 30 covid-19 patients for the study will be enrolled. all the patients enrolled were confirmed to be infected with sars-cov-2 by rt-pcr assay for nasal and pharyngeal swab specimens. for the study, serum samples of the 30 patients will be collected and will be investigated for the detection rate for immunoglobulin g (igg). the first sample will be collected 2 weeks after the second negative rt-pcr assay for nasal and pharyngeal swab specimens and 6 samples will be collected after that for 6 months later; one serum sample tested every month for 6 months after. the following questions will be addressed:- 1. what proportion of confirmed cases develops specific igg antibodies to sars-cov-2? 2. how long is the duration of detection of serum igg antibodies and antibody titres over time following infection with sars-cov-2?

Eligibility criteria:
inclusion criteria: * patients with recent covid- 19 infection(2 weeks after the second negative rt-pcr assay) exclusion criteria: * patients on immune-suppressive therapy * patients with immunological disease

Keywords: covid19 igg
autologous transplantation for multiple myeloma

Conditions: Multiple Myeloma

Summary: the present study was designed in an attempt to prospectively evaluate in a randomized fashion whether further cytotoxic dose intensification, as delivered with two sequential autologous stem-cell transplantations, improved the outcome of younger patients with newly diagnosed multiple myeloma in comparison with a single autologous transplantation.

following demonstration that single autologous transplantation for the treatment of younger patients with newly diagnosed multiple myeloma prolonged overall survival in comparison with conventional chemotherapy, double autologous transplantation was tested, initially in refractory myeloma and subsequently to include also patients with newly diagnosed disease. to explore the role of double autologous stem-cell transplantation as part of up-front therapy for multiple myeloma, in 1996 we launched a prospective, randomized trial comparing a single course of stem-cell-supported melphalan with the same regimen followed, after three to six months, by a second autologous transplantation in support of melphalan and busulfan. the study was designed to detect a 15 percent increase in complete or near complete response rate with double transplants compared to a single transplantation. with a 2-sided significance level α = 0.05 and a power 1-β = 0.80, 162 patients were required in each treatment arm of the study to detect a statistically significant increase in complete or near complete response rate from 30% in the single-transplant arm to 45% in the double-transplant arm. primary study endpoint was the complete or near complete response rate. secondary study endpoints were relapse-free survival, event-free survival and overall survival. the recruitment target was 324 patients.

Eligibility criteria:
inclusion criteria: * previously untreated * younger than 61 years * symptomatic myeloma * measurable disease * fit to receive high-dose chemotherapy exclusion criteria: * m-gus * solitary plasmacytoma * plasma cell leukemia * al amyloidosis

Keywords: myeloma previously untreated single autologous transplantation double autologous transplantation complete response
effect of vitamin d supplement on osteoprotegin expression and disease progression in patients with chronic kidney disease stage 1 and 2

Conditions: Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2

Summary: vitamin d supplement in patients with ckd stage 1 and 2 may change osteoprotegin expression so as to produce beneficial effects of cardiovascular、bone metabolism and ckd progression.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ckd stage 1 and 2 * age \>18 years * ability to provide informed consent exclusion criteria: * on vitamin d in past 4 weeks * plans to relocate out of taixing city in the next one year * serum phosphate \>5.5 mg/dl in past 3 months * serum calcium \>10.0 mg/dl in past 3 months * cancer * transplanted organ * rapidly deteriorating kidney function with the expectation for initiation of dialysis in less than 6 months

Keywords: calcitrol bone mineral density osteoprotegin vascular calcification
donepezil attenuate postoperative cognitive dysfunction

Conditions: Osteoarthritis; Femoral Head Necrosis; Rheumatoid Arthritis

Summary: postoperative cognitive dysfunction (pocd) occurs mainly in aged patients. pocd may increase the mortality and morbidity. however, the mechanism of pocd is not clear yet and no effective therapy method was proved. according to our previous study, the central cholinergic system impaired by the anesthesia and surgery play a very important role in the pocd and donepezil an acetylcholinesterase inhibitor can prevent the pocd after isoflurane anesthesia in aged mice. donepezil is a commercial medicine used for the alzheimer disease, which is tolerable and has minimal adverse events. in present study a multi-center randomized case control study was conducted and we hypothesized that donepezil attenuate the pocd.


Eligibility criteria:
inclusion criteria: 1. elder than 60 years old 2. speak chinese mandarin 3. those who will undergo knee or hip replacement 4. signed the inform consent 5. american society of anesthesiologists classification i to iii exclusion criteria: 1. existing cerebral disease, or have a history of neurological and psychiatric diseases including alzheimer disease, stroke, epilepsy and psychosis; 2. existing cognitive impairment as evidenced by mini-mental state examination scores below 24; 3. several audition or vision disorder; 4. unwillingness to comply with the protocol or procedures. 5. can not communicated with chinese mandarin 6. existing bradycardiac arrhythmia（heart rate \<60 bpm for any reasons） 7. existing gastrointestinal ulcer 8. existing urinary incontinence 9. existing asthma or chronic obstructive pulmonary disease 10. allegory to donepezil

Keywords: postoperative cognitive dysfunction donepezil hip replacement knee replacement postoperative delirium
speaking valve influence on breathing, swallowing and vocal functions in patients with tracheostomy.

Conditions: Tracheostomy

Summary: speaking valve seems to have a beneficial influence on breathing and secretion management in certain patients with tracheostomy. the investigators plan to use a speaking valve during respiratory physical therapy sessions in participants with disturbances of consciousness, who have a tracheostomy, with no need of a mechanical ventilation.


Eligibility criteria:
inclusion criteria: * brain injury (traumatic/non-traumatic). * tracheostomy. * unresponsive wakefulness syndrome or minimally conscious state. * fiber optic examination as follows: good mobilization of the vocal cords. no airway granulation, marianjoy scale score: 1-3. * the legal guardian speaks hebrew. exclusion criteria: * airway stenosis / inflammation. * oxygen saturation \<90%.
a study to determine the relief of dry eye symptoms with the use of theratears® products (dunlin)

Conditions: Dry Eye Syndromes

Summary: dry eye is a very common condition that most often affects women and the elderly, and can be caused when the eyes do not produce enough tears, or when the tears evaporate too quickly. although there isn't a simple cure for dry eye, there are numerous products on the market that attempt to help relieve some of the discomfort caused by this condition. some of these products include artificial tears, omega-3 supplements, and/or anti-inflammatory medications. the purpose of this study is to evaluate the performance of a combination of theratears® products, and to compare them with the product(s) you have been using.


Eligibility criteria:
inclusion criteria: 1. is between 18 and 65 years of age and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. is willing and able to follow instructions and maintain the appointment schedule; 4. exhibits symptoms of dry eye for at least 3 months; 5. has an osdi score of ≥ 23; 6. is currently on a non-omega 3 dry eye treatment regimen that, at the minimum consists of instilling artificial tears at least once a day for the past 3 months; 7. has an average non-invasive tear breakup time ≤ 5.00 seconds in at least one eye. exclusion criteria: 1. is participating in any concurrent clinical or research study; 2. has any known active\* ocular disease and/or infection and/or allergies; \* for the purposes of study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are typical findings and are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active. 3. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 5. has known sensitivity to the diagnostic pharmaceuticals to be used in the study; 6. is pregnant, lactating or planning a pregnancy at the time of enrollment, as determined verbally; 7. is aphakic; 8. has undergone refractive error surgery; 9. has taken part in another (pharmaceutical) research study within the last 30 days; 10. has worn contact lenses within the past 5 years; 11. is currently using or have used omega 3 supplements in the past 3 months.